SCHEDULE 13G 0002089463 XXXXXXXX LIVE Common Stock, $0.0001 par value per share 10/20/2025 0001789192 N2OFF, Inc. 80512Q302 HaPardes 134 (Meshek Sander) Neve Yarak L3 4994500 Rule 13d-1(c) Alon Silberman b L3 454127.00 0.00 454127.00 0.00 454127.00 N 16.93 IN Alon Silberman is an individual and the Chief Executive Officer of MitoCareX Bio Ltd., a wholly owned subsidiary of the Issuer. The 454,127 shares of common stock, par value $0.0001 per share ("Common Stock"), beneficially owned by the Reporting Person were acquired as part of the Securities Purchase and Exchange Agreement, as amended, dated February 25, 2025. Percentage of class represented in Row 11 is based on 2,682,483 shares of Common Stock issued and outstanding as of the date of this Schedule 13G, according to information provided by the Issuer. N2OFF, Inc. HaPardes 134 (Meshek Sander), Neve Yarak, L3, 4994500 Dr. Alon Silberman 40 Gordon Street, Givatayim, Israel, 5322709 Israel Y See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein. See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein. See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein. See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein. See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein. See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Alon Silberman /s/Alon Silberman 10/28/2025